GlobeNewsWire
24 Aug 2026, 10:47 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Capricor's lead candidate, Deramiocel, for DMD-associated cardiomyopathy. — Failure to prove efficacy for a lead product candidate is a catastrophic event for a biotech company's valuation and pipeline.
-0.90The FDA raised concerns regarding post-hoc changes to Capricor's statistical analysis plan and primary endpoint calculations performed shortly before data unblinding. — Allegations of data manipulation or improper analysis undermine the credibility of clinical results and increase regulatory rejection risk.
-0.70Capricor Therapeutics is facing a securities fraud class action lawsuit alleging misstatements regarding clinical data integrity and FDA communications. — Legal liabilities and fraud allegations create additional financial overhead and reputational damage beyond the clinical failure.
-0.40Continue reading
6 related stories
Search tags
The FDA previously issued a Complete Response Letter stating that Deramiocel's Biologics License Application did not meet statutory requirements for substantial evidence of effectiveness. — Confirms a formal regulatory setback, although this was a preceding event to the recent price collapse.
-0.30Which stocks this story touches
The company is facing a securities fraud class action lawsuit following a massive stock drop and FDA concerns regarding the efficacy and data integrity of its lead product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
